小檗碱及其盐类药物的制剂学研究进展

摘要/Abstract

摘要：

小檗碱最早是从黄连等中草药中提取得到的一种异喹啉类生物碱，具有抗病毒，抗菌，调节脂质和糖代谢，抑制肿瘤细胞增殖，抗炎，诱导细胞凋亡等多种药理作用。但因其水溶性差，口服吸收效果差，且具有一定的心肌毒性等因素阻碍了小檗碱的临床应用。为了克服这些缺点，不同的药物递送技术已被广泛用于小檗碱制剂的研究中。本文总结了成盐、共晶、环糊精包合物、纳米技术等制剂策略在小檗碱研究中的应用，旨在为该领域的进一步研究提供参考。

关键词: 小檗碱, 成盐, 共晶, 包合物, 纳米技术

Abstract:

Objective：Berberine is an isoquinoline alkaloid first extracted from medicinal Chinese herbs like Coptis chinensis etc. It has many pharmacological effects including anti-viral, anti-microbial, regulating lipid and glucose metabolism, inhibiting tumor cell proliferation, anti-inflammatory, inducing cell apoptosis and so on. However, poor water solubility, poor oral absorption, and some cardiac toxicity hinder the clinical application of berberine. In order to overcome its disadvantages, various drug delivery technologies have been widely used in the study of berberine. In this article, we summarized the preparation strategies like salt formation, eutectic, cyclodextrin inclusion and nanotechnology in the study of berberine, in order to provide reference for further studies in this field.

Key words: Berberine, Salt formation, Eutectic, Inclusion complex, Nanotechnology

中图分类号:

R283.5

陈跃杰, 周雪, 朱丹.

小檗碱及其盐类药物的制剂学研究进展 [J]. 中国药物评价, 2022, 39(2): 140-147.

CHEN Yue-jie, ZHOU Xue, ZHU Dan.

Progress in the Formulation of Berberine and Its Salts [J]. CHINESE JOURNAL OF DRUG EVALUATION, 2022, 39(2): 140-147.

参考文献

[1] 李波，朱维良，陈凯先. 小檗碱及其衍生物的研究进展[J]. 药学学报， 2008, 43 (8)：773-787.

[2] 林媛，司书毅，蒋建东. 小檗碱的抗菌作用[J]. 药学学报， 2018, 53(2)：163-168.

[3] Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol lowering drug working through a unique mechanism distinct from statins[J]. Nat Med, 2004, 10(12): 1344-1351.

[4] Zhang Z, Zhang H, Li B, et al. Berberine activates thermogenesis in white and brown adipose tissue[J]. Nat Commun, 2014, 5：5493.

[5] Zhang Q, Xiao X, Feng K, et al. Berberine moderates glucose and lipid metabolism through multipathway mechanism[J]. Evid Based Complement Alternat Med, 2011, 2011：924851.

[6] Wu HL, Chuang TY, Al-Hendy A, et al. Berberine inhibits the proliferation of human uterine leiomyoma cells[J]. Fertil Steril, 2015, 103(4)：1098-1106.

[7] Tan W, Li N, Tan, et al. Berberine interfered with breast cancer cells metabolism，balancing energy homeostasis[J]. Anti-Cancer Age Med Chem, 2015, 15 (1): 66-78.

[8] Hao X, Yao A, Gong J, et al. Berberine ameliorates pro-inflammatory cytokine-induced endoplasmic reticulum stress in human intestinal epithelial cells in vitro[J]. Inflammation, 2012, 35(3): 841-849.

[9] Hu J, Chai Y, Wang Y, et al. PI3K p55γ promoter activity enhancement is involved in the anti-apoptotic effect of berberine against cerebral ischemia-reperfusion[J]. Eur J Pharmacol, 2012, 674 (2 /3): 132142.

[10] 王雪超，杜美容. 盐酸小檗碱溶解度与相分配系数研究[J]. 河北北方学院学报 (自然科学版), 2011，1(27): 26-29.

[11] 林媛，张红娟，韩燕星，等.小檗碱对肠道菌的抑制作用[J]. 中国医药生物技术， 2018, 4(13): 335-338.

[12] Cui HX, Hu YN, Li JW, et al. Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability[J]. Molecules, 2018, 24(1)：103.

[13] Lu Q, Dun J, Chen JM, et al. Improving solid-state properties of berberine chloride through forming a salt cocrystal with citric acid[J]. Int J Pharm, 2019, 554：14-20.

[14] 刘书妤，卢琪. 盐酸小檗碱与乳酸共晶、其制备方法和应用[S]. CN 109400598 A.2019-03-01.

[15] Yang D, Cao J, Jiao L, et al. Solubility and Stability Advantages of a New Cocrystal of Berberine Chloride with Fumaric Acid[J]. ACS Omega, 2020, 5(14)：8283-8292.

[16] Wang L, Liu S, Chen JM, et al. Novel Salt-Cocrystals of Berberine Hydrochloride with Aliphatic Dicarboxylic Acids: Odd-Even Alternation in Physicochemical Properties[J]. Mol Pharm, 2021, 18(4)：1758-1767.

[17] Deng Y, Zhang Y, Huang Y, et al. Preparation, Crystal Structures, and Oral Bioavailability of Two Cocrystals of Emodin with Berberine Chloride[J]. Cryst Growth Des, 2018, 18(12)：7481-7488.

[18] Sa R, Zhang Y, Deng Y, et al. Novel Salt Cocrystal of Chrysin with Berberine: Preparation, Characterization, and Oral Bioavailability[J]. Cryst Growth Des, 2018，18 (8): 4724-4730.

[19] Zhang YJ, Lou BY, Huang YL, et al. Crystal structure, stability and dissolution of a drug-drug molecular salt hydrate of berberine with protocatechuic acid[J]. Chinese J Struc Chem, 2018, 37(3): 400-406.

[20] Li P, Ramaiah T, Zhang M, et al. Two Cocrystals of Berberine Chloride with Myricetin and Dihydromyricetin: Crystal Structures, Characterization, and Antitumor Activities[J]. Cryst Growth Des, 2020, 20(1): 157-166.

[21] Guan X, Jiang L, Cai L, et al. A New Co-Crystal of Synthetic Drug Rosiglitazone with Natural Medicine Berberine: Preparation, Crystal Structures, and Dissolution[J]. Molecules, 2020, 25(18)：4288.

[22] He A, Kang X, Xu Y, et al. Investigation on intermolecular interaction between berberine and β-cyclodextrin by 2D UV-Vis asynchronous spectra[J]. Spectrochim Acta A Mol Biomo Spectrosc, 2017, 185：343-348.

[23] Zhang Y, Cui YL, Gao LN, et al. Effects of β-cyclodextrin on the intestinal absorption of berberine hydrochloride, a P-glycoprotein substrate[J]. Int J Biol Macromol, 2013, 59：363-371.

[24] Huang L, Chen X, Nguyen TX, et al. Nano-cellulose 3D-networks as controlled-release drug carriers[J]. J Mater Chem B, 2013，1(23)：2976-2984.

[25] Xiao L, Poudel AJ, Huang L, et al. Nanocellulose hyperfine network achieves sustained release of berberine hydrochloride solubilized with β-cyclodextrin for potential anti-infection oral administration[J]. Int J Biol Macromol, 2020, 153：633-640.

[26] Ma S, Wang Y, Shang X, et al. Formulation of Berberine Hydrochloride and Hydroxypropyl-β-Cyclodextrin Inclusion Complex with Enhanced Dissolution and Reduced Bitterness[J]. Trop J Pharm Res, 2012, 11 (6): 871-877.

[27] Wang QS, Li K, Gao LN, et al. Intranasal delivery of berberine via in situ thermoresponsive hydrogels with non-invasive therapy exhibits better antidepressant-like effects[J]. Biomater Sci, 2020, 8(10)：2853-2865.

[28] Sahibzada MUK, Sadiq A, Faidah HS, et al. Berberine nanoparticles with enhanced in vitro bioavailability: characterization and antimicrobial activity[J]. Drug Des Devel Ther, 2018，12：303-312.

[29] Wang Z, Wu J, Zhou Q, et al. Berberine nanosuspension enhances hypoglycemic efficacy on streptozotocin induced diabetic C57BL/6 mice [J]. Evid Based Complement Alternat Med, 2015：239749.

[30] Xu H, Yuan XD, Shen BD, et al. Development of poly(N-isopropylacrylamide) /alginate copolymer hydrogel-grafted fabrics embedding of berberine nanosuspension for the infected wound treatment[J]. J Biomater Appl, 2014, 28(9)：1376-1385.

[31] Xie YY, Zhang YW, Liu XZ, et al. Aggregation-Induced Emission-Active Amino acid/Berberine Hydrogels with Enhanced Photodynamic Antibacterial and Anti-biofilm Activity[J]. Chemical Engineering Journal, 2021，413：127542.

[32] Freag MS, Torky AS, Nasra MM, et al. Liquid crystalline nanoreservoir releasing a highly skin-penetrating berberine oleate complex for psoriasis management[J]. Nanomedicine, 2019，14(8)：931-954.

[33] Al-Awady MJ, Fauchet A, Greenway GM, et al. Enhanced antimicrobial effect of berberine in nanogel carriers with cationic surface functionality[J]. J Mater Chem B, 2017, 5(38)：7885-7897.

[34] Amato G, Grimaudo MA, Alvarez-Lorenzo C, et al. Hyaluronan/Poly-L-lysine/Berberine Nanogels for Impaired Wound Healing[J], Pharmaceutics，2020, 13(1)：34.

[35] Zhang P, He L, Zhang J, et al. Preparation of novel berberine nano-colloids for improving wound healing of diabetic rats by acting Sirt1/NF-κB pathway[J]. Colloids Surf B Biointerfaces, 2020, 187：110647.

[36] Duong TT, Isom？ki A, Paaver U, et al. Nanoformulation and Evaluation of Oral Berberine-Loaded Liposomes[J]. Molecules, 2021, 26(9)：2591.

[37] Zhou W, An X, Wang J, et al. Characteristics, phase behavior and control release for copolymer–liposome with both pH and temperature sensitivities [J]. Colloid Surface A, 2012, 395: 225-232.

[38] Li J, Hao L, Zhang X, et al. Using Magnetic and Photic Stimuli-Responsive Liposomes to Serve Up Chemotherapy Drugs to Cancer Cells[J]. J Biomed Nanotechnol, 2020, 16(6)：867-875.

[39] Calvo A, Moreno E, Larrea E, et al. Berberine-Loaded Liposomes for the Treatment of Leishmania infantum-Infected BALB/c Mice[J]. Pharmaceutics, 2020, 12(9)：858.

[40] Wang X, Wang Q, Liu Z, et al. Preparation, pharmacokinetics and tumour-suppressive activity of berberine liposomes[J]. J Pharm Pharmacol, 2017, 69(6)：625-632.

[41] Lin YH, Lin JH, Chou SC, et al. Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: in vitro and in vivo study[J]. Nanomedicine (Lond), 2015, 10(1)：57-71.

[42] Yu M, Jambhrunkar S, Thorn P, et al. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells[J]. Nano, 2013, 5(1): 178，183.

[43] Lee T, Lim E-K, Lee J, et al. Efficient CD44-targeted magnetic resonance imaging (MRI) of breast cancer cells using hyaluronic acid (HA)-modified MnFe2O4 nanocrystals[J]. Nanoscale Res Lett, 2013, 8(1)：149.

[44] Bhatnagar P, Kumari M, Pahuja R, et al. Hyaluronic acid-grafted PLGA nanoparticles for the sustained delivery of berberine chloride for an efficient suppression of Ehrlich ascites tumors[J]. Drug Deliv Transl Res, 2018, 8(3)：565-579.

[45] Sailor GU, Ramani VD, Shah N, et al. Design of Experiment Approach Based Formulation Optimization of Berberine Loaded Solid Lipid Nanoparticle for Antihyperlipidemic Activity [J]. Indian J Pharm Sci, 2021, 83(2)：204-218.

[46] Ruan C, Liu L, Lu Y, et al. Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma[J]. Acta Pharm Sin B, 2018, 8(1)：85-96.

[47] Zhang Y, Wang L, Li G, et al. Berberine-Albumin Nanoparticles: Preparation, Thermodynamic Study and Evaluation Their Protective Effects Against Oxidative Stress in Primary Neuronal Cells as a Model of Alzheimer′s Disease[J]. J Biomed Nanotechnol, 2021, 17(6)：1088-1097.